Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Good-The Bad and The Ugly -- Ignore unavailable to you. Want to Upgrade?

To: Tim Luke who wrote (4071)	11/13/2000 9:01:46 PM
From: Jane4IceCream	Respond to of 8686

Oh! <I get it> LOL! colonize.com Jane

To: Tim Luke who wrote (4071)	11/13/2000 9:24:32 PM
From: Tim Luke	Read Replies (1) \| Respond to of 8686

SuperGen's Nipent 'Extremely Active' in Refractory Blood Cancers Using Combination Therapy Data Recently Presented by Two Independent Groups at 18th Chemotherapy Foundation Symposium SAN RAMON, Calif., Nov. 13 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG & SUPGZ) announced today that data from two separate studies reported recently at the 18th Annual Mount Sinai School of Medicine's XVIII Chemotherapy Foundation Symposium concluded that the company's anticancer compound pentostatin (Nipent(R)), in combination therapy, is 'extremely active' in several refractory blood cancers. On Saturday, November 11th, data was presented from two current clinical studies using pentostatin (Nipent) in combination therapy for patients with low-grade lymphoma and chronic lymphocytic leukemia (CLL). In the report of a multi-centered U.S. Oncology study, Dr. Robert Drapkin from Florida Infusion Centers stated that the combination of pentostatin (Nipent) and Rituximab is "so active in low grade B-cell lymphoma and in CLL, that the response rate in the pilot study was nearly 100 percent. Furthermore, the combination therapy is so well tolerated that patients in their 90s have safely been treated," stated Dr. Drapkin. There are 51 patients currently enrolled in Dr. Drapkin's studies. Data from the second study, using pentostatin (Nipent) and Cyclophosphamide in previously treated patients with CLL, was presented by Dr. Mark Weiss from the Leukemia Service at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Weiss demonstrated that the pentostatin (Nipent) and Cyclophosphamide combination therapy resulted in various bone marrow-sparing activities, including the increase in the number of platelets (blood clotting elements) in the blood and a dramatic decrease in the number of white blood cells. Dr. Weiss currently has 21 patients enrolled, and the data presented on the first 14 evaluable patients showed an overall response rate of 71 percent and a complete response rate of 22 percent. In 43 percent of the patients, the response to the pentostatin (Nipent) combination therapy was superior to the response achieved in other treatments, including the patient's initial therapy. "The combination of pentostatin (Nipent) and Cyclophosphamide is extremely active," said Dr. Weiss. "It is the most active regimen I have used to treat patients with CLL." "These studies serve as evidence of Nipent's efficacy in an increasing number of hematological malignancies," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "Moving these additional indications forward in the clinical development of Nipent is a high priority." Based in San Ramon, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. This press release contains 'forward-looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements, including those regarding the clinical development of Nipent involve certain risks and uncertainties associated with an emerging pharmaceutical company. Actual results could differ materially from those projected in the 'forward-looking' statements as a result of failure to obtain the clinical data necessary to support marketing approval for Nipent in the U.S., unforeseen delays in clinical trial management, adverse FDA actions, matters arising out of the Company's agreement with Abbott Laboratories as well as other risk factors discussed in SuperGen's reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, the report on Form 10-K for the year ended December 31, 1999, and the report filed on Form 10-Q for the three months ended June 30, 2000). /CONTACT: L. Robert Cohen, Vice President, Investor Relations, 800-353-1075, ext. 243, or Dr. Joseph Rubinfeld, Chairman & CEO, 800-353-1075, ext. 230, both of SuperGen Inc./ 10:39 EST